leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals appoints highly experienced sales director to implement global growth strategy

The new sales director has held senior sales and business development positions at multi-national healthcare companies.

MGC Pharmaceuticals Ltd -
MGC is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKT:MGCLF) has appointed highly experienced sales director Nicole Godresse as its new global chief sales officer, effective immediately.

Godresse will lead the company’s global sales and marketing initiatives across Australia and New Zealand as well as build and implement a strong and focused pharma sales strategy by recruiting a highly experienced sales force around the world.

The new strategy will be rolled out following the completion of the integration of the recently acquired Medicinal Cannabis Clinics and the board is confident it will deliver strong commercial results taking the company through to its next phase of growth, as an Australian market leader.

Godresse has more than 20 years’ experience in the pharmaceutical and healthcare industry, holding senior commercial roles with major multi-national companies including Eli Lilly, Johnson & Johnson, Schering-Plough, Merck Sharp & Dohme and most recently Tilray.

"New and refocused growth strategy"

Co-founder and MD Roby Zomer said: “We are delighted to welcome Nicole to the team and are extremely impressed with her experience and expertise.

“MGC Pharma delivered significant commercial progress during 2020 and we are focused on ensuring this trajectory continues with a new and refocused accelerated growth strategy.”

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.026 AUD

ASX:MXC
Market: ASX
Market Cap: $46.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19

MGC Pharmaceuticals Ltd’s (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer speaks to Proactive's Andrew Scott following the publication of results in its phase II double blind clinical trial of ArtemiC in COVID-19 patients. The results show the treatment improved the clinical recovery of all...

on 12/14/2020

2 min read